Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Raises $6M in Direct Offering, Regains Nasdaq Compliance with Bid Requirement

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday that it has netted proceeds of about $6 million from a direct offering, and that it has regained compliance on at least one of two Nasdaq listing requirements that it previously failed to meet.

It added that it believes it has regained compliance with the second listing requirement.

In a document filed with the US Securities and Exchange Commission, the Israel-based molecular diagnostics firm said that it closed its direct offering on Thursday, selling 570,755 ordinary shares at $11.50 per share to various investors. Rosetta announced the direct offering last week.

Proceeds from the sale will go toward operations and other general corporate purposes, Rosetta said, including repayment or refinancing of existing debt, working capital, IP protection and enforcement, R&D, investments, and acquisitions.

It said that its existing funds, along with proceeds from the offering, will be able to fund its operations for at least the next 16 months.

Rosetta also said that it is now in compliance with a Nasdaq listing requirement calling for a closing bid price on its stock of at least $1. The company was warned by the exchange of its non-compliance in December and was given until May 29 to regain compliance by raising the bid price at or above $1 for at least 10 consecutive days.

On May 30, Rosetta received notification from Nasdaq that it had met that listing requirement.

The company added that as a result of $6 million direct offering it believes it is in compliance with another Nasdaq listing requirement calling for at least $2.5 million in stockholders' equity. Rosetta was warned in April that it was not in compliance with that requirement.

It is awaiting confirmation from Nasdaq that it fulfills all applicable requirements for continued listing on the Nasdaq Capital Market, it said in its SEC document.

Rosetta's fortunes have dramatically turned around recently after receiving a favorable coverage decision from designated Medicare contractor Novitas for its miRview mets2 assay for identifying tumor of origin in primary and metastatic cancer, including cancer of unknown or uncertain primary.

In addition, the firm recently effected a reverse one-for-15 reverse stock split which helped push up its share price. On May 14, the day before the reverse stock split, Rosetta's shares closed at $.14.

In Friday morning trade shares of Rosetta were down 3 percent at $13.35.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.